Belite Bio, Inc (BLTE) Stock

About Belite Bio, Inc

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

Belite Bio, Inc is headquartered in US.

Belite Bio, Inc (BLTE) stock trades at $157.14 with a market capitalization of $6.30B. The stock is valued at a negative price-to-earnings (P/E) ratio of -61.62, reflecting a net loss over the last twelve months, price-to-book of 7.87, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $60.00 and $200.00, and currently trades 21.4% below its 52-week high.

On profitability, Belite Bio, Inc generates a return on equity (ROE) of -18.14% (negative, reflecting a net loss), return on capital employed of -12.74%.

Official website: belitebio.com

Belite Bio, Inc by the numbers, 2020–2025

Between 2020 and 2025 Belite Bio, Inc reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-78.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-90.0M.

Borrowings fell from $32.0M to $0, cash on hand is $0, cash from operations was $-37.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged -6.9% over five years, and was -10.1% in the most recent year.

The share price itself has compounded at —% a year over five years, 108.0% over three, 163.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Belite Bio, Inc (BLTE) — frequently asked questions